ECSP099490A - Métodos de fabricación y uso de compuestos y composiciones - Google Patents

Métodos de fabricación y uso de compuestos y composiciones

Info

Publication number
ECSP099490A
ECSP099490A EC2009009490A ECSP099490A ECSP099490A EC SP099490 A ECSP099490 A EC SP099490A EC 2009009490 A EC2009009490 A EC 2009009490A EC SP099490 A ECSP099490 A EC SP099490A EC SP099490 A ECSP099490 A EC SP099490A
Authority
EC
Ecuador
Prior art keywords
methods
compositions
manufacture
compounds
psychiatric
Prior art date
Application number
EC2009009490A
Other languages
English (en)
Inventor
Boyd Lynn Harrison
Chiara Ghiron
Hendrick Bothmann
Arianna Nencini
Iolanda Micco
Riccardo Zanaletti
Laura Maccari
Simon Haydar
Maurizio Varrone
Carmela Pratelli
Original Assignee
Siena Biotech Spa
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siena Biotech Spa, Wyeth Corp filed Critical Siena Biotech Spa
Publication of ECSP099490A publication Critical patent/ECSP099490A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención provee compuestos y composiciones, métodos para su fabricación y métodos para su uso a fin de modular los receptores nicotínicos de acetilcolina ?7 y/o para el tratamiento de cualquiera de los diversos trastornos, enfermedad y factores. Los compuestos provistos pueden afectar, entre otras cosas, al sistema neurológico, psiquiátrico y/o inflamatorio.
EC2009009490A 2007-01-16 2009-07-03 Métodos de fabricación y uso de compuestos y composiciones ECSP099490A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88062907P 2007-01-16 2007-01-16

Publications (1)

Publication Number Publication Date
ECSP099490A true ECSP099490A (es) 2009-09-29

Family

ID=39345157

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009490A ECSP099490A (es) 2007-01-16 2009-07-03 Métodos de fabricación y uso de compuestos y composiciones

Country Status (24)

Country Link
US (1) US8163729B2 (es)
EP (1) EP2118067B1 (es)
JP (1) JP2010515770A (es)
KR (1) KR20090116707A (es)
CN (1) CN101679287B (es)
AR (1) AR064921A1 (es)
AU (1) AU2008206759B2 (es)
BR (1) BRPI0806665A2 (es)
CA (1) CA2675676A1 (es)
CL (1) CL2008000119A1 (es)
CO (1) CO6351782A2 (es)
CR (1) CR10930A (es)
EA (1) EA016948B1 (es)
EC (1) ECSP099490A (es)
IL (1) IL199889A0 (es)
MX (1) MX2009007615A (es)
NZ (1) NZ578411A (es)
PA (1) PA8766201A1 (es)
SA (1) SA08290018B1 (es)
SV (1) SV2009003334A (es)
TW (1) TW200901974A (es)
UA (1) UA98317C2 (es)
WO (1) WO2008087529A1 (es)
ZA (1) ZA200904943B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
WO2009091832A1 (en) * 2008-01-14 2009-07-23 Wyeth Synthesis of pyrazoles
WO2009091813A1 (en) * 2008-01-14 2009-07-23 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
WO2009091831A1 (en) * 2008-01-14 2009-07-23 Wyeth Compound forms and uses thereof
TW201004941A (en) * 2008-07-16 2010-02-01 Wyeth Corp Alpha7 nicotinic acetylcholine receptor inhibitors
MX2011001887A (es) 2008-08-22 2011-04-04 Baxter Int Derivados de bencil carbonato polimericos.
CA2754180A1 (en) * 2009-03-09 2010-09-16 The Regents Of The University Of California Substituted heterocycles and their use as allosteric modulators of nicotinic and gabaa receptors
JP2012533601A (ja) * 2009-07-23 2012-12-27 ノバルティス アーゲー 運動失調症の処置または予防のための、アザビシクロアルキル誘導体またはピロリジン−２−オン誘導体の使用
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
US8815271B2 (en) * 2010-11-03 2014-08-26 Dow Agrosciences, Llc. Pesticidal compositions and processes related thereto
US20130231290A1 (en) * 2010-11-18 2013-09-05 Dignity Health Methods of diagnosing and treating neurodegenerative diseases
JPWO2014054635A1 (ja) * 2012-10-02 2016-08-25 大日本住友製薬株式会社 イミダゾール誘導体
CN105254564A (zh) * 2015-10-31 2016-01-20 丁玉琴 一种2-甲基-3,4-二硝基-5-(甲氧苯基)吡唑的合成方法
CN105646358B (zh) * 2016-03-01 2018-03-09 苏州艾缇克药物化学有限公司 一种3‑氨基‑5‑(4‑甲氧苯基)吡唑的合成方法
CN109748873B (zh) * 2017-11-08 2021-02-02 北京嘉林药业股份有限公司 化合物及其治疗癌症的用途
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
AR114465A1 (es) 2018-04-04 2020-09-09 Japan Tobacco Inc Compuestos de pirazol sustituidos con heteroarilo y su utilización farmacéutica
GB202006382D0 (en) 2020-04-30 2020-06-17 Spermatech As Use
CN113925606B (zh) * 2021-10-25 2023-07-07 四川大学华西医院 一种神经调控导航定位方法、装置和神经调控治疗系统
JP7838764B2 (ja) * 2022-01-14 2026-04-01 学校法人慈恵大学 新型コロナウイルス感染症後遺症の治療薬

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU167263B (es) 1973-02-12 1975-09-27
DE2527677A1 (de) * 1975-06-21 1977-01-20 Bayer Ag Verfahren zur herstellung von 2,4- dioxo-1,2,3,4-tetrahydro-s-triazino- eckige klammer auf 1,2-a eckige klammer zu -benzimidazolen
US4624954A (en) * 1985-12-20 1986-11-25 American Home Products Corporation 6,7,8,9-tetrahydro-10-methylpyrido[1,2-a]indol-9-amines and derivatives thereof, useful for the treatment of cognitive impairments
US4665183A (en) 1985-12-20 1987-05-12 American Home Products Corp. Process for preparing 6,7,8,9-tetrahydro-10-methylpyrido[1,2-a]indol-9-amines and derivatives thereof useful for the treatment of cognitive impairments
US5219857A (en) 1986-10-16 1993-06-15 American Cyanamid Company Method of treating cognitive and related neural behavioral problems
US4904658A (en) * 1988-04-15 1990-02-27 American Cyanamid Company Substituted-6H,8H-pyrimido-[1,2,3-cd]purine-8,10-(9H)-diones and substituted-6H,10H-pyrimido[1,2-cd]purin-10-ones
US5260331A (en) * 1989-01-02 1993-11-09 John Wyeth & Brother Limited Composition for treating depression with (S- or O-heteroaryl)alkyl amines
US5422355A (en) * 1989-06-02 1995-06-06 John Wyeth & Brother, Limited Composition for treating depression with (N-heteroaryl)alkylamines
FR2655988B1 (fr) 1989-12-20 1994-05-20 Adir Cie Nouveaux derives de la napht-1-yl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
IE911774A1 (en) 1990-06-11 1991-12-18 Akzo Nv Pyridinylpiperazine derivatives
IL101722A (en) 1991-05-02 1996-05-14 Wyeth John & Brother Ltd Piperazine derivatives their preparation and pharmaceutical compositions containing them
GB9125615D0 (en) * 1991-12-02 1992-01-29 Wyeth John & Brother Ltd Amines
EP0619814A1 (en) 1991-12-31 1994-10-19 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
JPH0616638A (ja) 1992-03-30 1994-01-25 Yoshitomi Pharmaceut Ind Ltd ピリジン化合物およびその医薬用途
EP1156043B1 (en) 1992-07-24 2003-11-12 The Regents Of The University Of California Drugs that enhance synaptic responses mediated by ampa receptors
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
ES2128544T3 (es) 1992-12-17 1999-05-16 Pfizer Pirrolopirimidinas como antagonistas del crf.
US5712303A (en) 1992-12-17 1998-01-27 Pfizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
CA2150703C (en) 1992-12-17 2002-01-08 Pfizer Limited Substituted pyrazoles
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
GB9302622D0 (en) 1993-02-10 1993-03-24 Wellcome Found Heteroaromatic compounds
EP0690051B1 (en) 1994-01-14 2001-07-18 Azwell Inc. Diazacycloalkanealkylsulfonamide derivative
JP3319651B2 (ja) * 1994-04-26 2002-09-03 富士写真フイルム株式会社 感光性転写シート
US5650409A (en) 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
GB9514901D0 (en) 1995-07-20 1995-09-20 American Home Prod Piperazine derivatives
US6288091B1 (en) * 1995-12-29 2001-09-11 Boehringer Ingelheim Ltd. Antiherpes virus compounds and methods for their preparation and use
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5736543A (en) 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
AU2897497A (en) 1996-05-11 1997-12-05 Smithkline Beecham Plc Tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors
GB9708694D0 (en) 1997-04-30 1997-06-18 Smithkline Beecham Plc Compounds
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
US6329368B1 (en) 1997-05-09 2001-12-11 The Regents Of The University Of California Endocrine modulation with positive modulators of AMPA type glutamate receptors
KR100247563B1 (ko) 1997-07-16 2000-04-01 박영구 키랄3,4-에폭시부티르산및이의염의제조방법
AU736596B2 (en) * 1997-07-25 2001-08-02 H. Lundbeck A/S Indole and 2,3-dihydroindole derivatives, their preparation and use
US6632823B1 (en) 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
CA2320354A1 (en) 1998-02-18 1999-08-26 Neurosearch A/S Novel compounds and their use as positive ampa receptor modulators
AU762726B2 (en) 1998-03-31 2003-07-03 Acadia Pharmaceuticals, Inc. Compounds with activity on muscarinic receptors
US6124278A (en) 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response
WO1999062505A2 (en) 1998-06-01 1999-12-09 Ortho-Mcneil Pharmaceutical, Inc. Method for treating neurodegenerative disorders
US6605623B1 (en) 1998-12-18 2003-08-12 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6313126B1 (en) 1999-01-07 2001-11-06 American Home Products Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
KR20010101675A (ko) * 1999-01-26 2001-11-14 우에노 도시오 2ｈ-프탈라진-1-온 유도체 및 그 유도체를 유효 성분으로하는 약제
US20010044445A1 (en) * 1999-04-08 2001-11-22 Bamaung Nwe Y. Azole inhibitors of cytokine production
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
WO2001032604A1 (en) 1999-11-05 2001-05-10 University College London Activators of soluble guanylate cyclase
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
WO2001057008A1 (en) * 2000-02-07 2001-08-09 Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
WO2001074773A2 (en) 2000-03-31 2001-10-11 Ortho Mcneil Pharmaceutical, Inc. Phenyl-substituted indoles as histamine h3-receptor antagonists
EP1268478B1 (en) 2000-03-31 2007-05-02 Ortho-McNeil Pharmaceutical, Inc. Phenyl-substituted imidazopyridines
OA12245A (en) 2000-04-10 2003-11-10 Pfizer Prod Inc Benzoamide piperidine compounds as substance P antagonists.
US6448276B1 (en) 2000-05-17 2002-09-10 Inspire Pharmaceuticals, Inc. Method for treating vaginal dryness with nicotinic acetylcholine receptor agonists
JP2004516237A (ja) 2000-06-21 2004-06-03 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー ケモカイン受容体活性調節剤としてのピペリジンアミド類
JP2002030073A (ja) 2000-07-19 2002-01-29 Ono Pharmaceut Co Ltd ４−（３−（４−モルホリノブチリルアミノ）フェニル）−２ｈ−フタラジン−１−オン・メタンスルホン酸塩・１水和物およびその製造方法。
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US20020173507A1 (en) 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
WO2002024694A1 (en) 2000-09-22 2002-03-28 Smithkline Beecham, P.L.C. Pyrazolopyridines and pyrazolopyridazines as antidiabetics
US6469007B2 (en) * 2000-11-28 2002-10-22 Wyeth Serotonergic agents
UA73619C2 (en) * 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
ES2267853T3 (es) * 2000-12-13 2007-03-16 Wyeth Inhibidroes de sulfonamida heteriociclicos de la produccion de beta amiloides.
ES2275853T3 (es) 2001-02-16 2007-06-16 Aventis Pharmaceuticals Inc. Derivados heterociclicos de urea y su uso como ligandos de receptores de dopamina d3.
ATE412638T1 (de) 2001-02-16 2008-11-15 Aventis Pharma Inc Heterocyclische substituierte carbonyl derivate und ihre verwendung als dopamin d3 rezeptor liganden
HUP0103987A3 (en) 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
HUP0103986A2 (hu) 2001-09-28 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
KR100579813B1 (ko) 2001-10-16 2006-05-12 주식회사 에스티씨나라 피페리딘 유도체, 이의 제조방법 및 이를 포함하는 치매치료용 약학적 조성물
US7402580B2 (en) * 2002-02-19 2008-07-22 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
DE10211415A1 (de) * 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
UA77814C2 (en) 2002-07-03 2007-01-15 Lundbeck & Co As H Spirocyclic piperidines as antagonists of mch1 and use thereof
GB0216233D0 (en) 2002-07-12 2002-08-21 Glaxo Group Ltd Compounds
CL2003001415A1 (es) * 2002-07-12 2005-01-07 Janssen Pharmaceutica Nv Compuestos d derivados de naftil, quinolinil e isoquinolinil urea; composicion farmaceutica; y uso en el tratamiento y prevencion de condiciones de dolor y en el sibndrome del colon irritable y condiciones asociadas.
TW200401641A (en) * 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
US7176198B2 (en) 2002-08-01 2007-02-13 Pfizer Inc. 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease
WO2004039366A1 (en) 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7186832B2 (en) * 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
TWI334868B (en) * 2003-06-03 2010-12-21 Nippon Kayaku Kk [1,2,4] triazoro [1,5-a] pyrimidine-2-ylurea derivative and use thereof
WO2005012311A1 (en) * 2003-07-31 2005-02-10 Wyeth N-sulfonylheterocyclopyrrolylalkylamine compounds as 5-hydroxytryptamine-6 ligands
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
EP1713809B1 (en) 2004-02-04 2009-07-29 Neurosearch A/S Dimeric azacyclic compounds and their use
EP1720886A1 (en) * 2004-03-02 2006-11-15 Wyeth Macrolides and methods for producing same
CA2556771A1 (en) * 2004-03-02 2005-09-15 Wyeth Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents
ES2332659T3 (es) 2004-06-16 2010-02-10 Wyeth Derivados de amino-5,5-difenilimidazolona para la inhibicion de beta-secretasa.
ATE423121T1 (de) 2004-06-16 2009-03-15 Wyeth Corp Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
BRPI0511993A (pt) 2004-07-20 2008-01-22 Siena Biotech Spa compostos moduladores de receptores de acetilcolina nicotìnicos alfa7, composições farmacêuticas e usos terapêuticos dos mesmos
JP2008510726A (ja) 2004-08-20 2008-04-10 エントレメッド インコーポレイテッド プロテイナーゼ活性化受容体アンタゴニストを含む組成物および方法
CA2594477C (en) 2005-01-21 2016-07-12 Astex Therapeutics Limited Pharmaceutical compounds
JP2008531596A (ja) 2005-02-25 2008-08-14 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｈｃｖ感染を治療または予防するのに有用なベンゾイソチアゾール
WO2007057750A2 (en) * 2005-11-15 2007-05-24 Inverness Medical Switzerland Gmbh Assays
AU2007219509A1 (en) * 2006-01-18 2007-09-07 Siena Biotech S.P.A Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
GB0723815D0 (en) 2007-12-05 2008-01-16 Glaxo Group Ltd Compounds
WO2009091832A1 (en) 2008-01-14 2009-07-23 Wyeth Synthesis of pyrazoles
WO2009091813A1 (en) 2008-01-14 2009-07-23 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
WO2009091831A1 (en) 2008-01-14 2009-07-23 Wyeth Compound forms and uses thereof
US20100016598A1 (en) * 2008-07-16 2010-01-21 Wyeth Alpha7 nicotinic acetylcholine receptor inhibitors
US20100016360A1 (en) * 2008-07-16 2010-01-21 Wyeth Alpha7 nicotinic acetylcholine receptor inhibitors
US20100016343A1 (en) * 2008-07-16 2010-01-21 Wyeth Alpha7 nicotinic acetylcholine receptor inhibitors
TW201004941A (en) 2008-07-16 2010-02-01 Wyeth Corp Alpha7 nicotinic acetylcholine receptor inhibitors

Also Published As

Publication number Publication date
WO2008087529A1 (en) 2008-07-24
EA016948B1 (ru) 2012-08-30
CN101679287A (zh) 2010-03-24
US20100029606A1 (en) 2010-02-04
HK1142335A1 (en) 2010-12-03
US8163729B2 (en) 2012-04-24
IL199889A0 (en) 2010-04-15
AU2008206759B2 (en) 2013-09-05
TW200901974A (en) 2009-01-16
SA08290018B1 (ar) 2013-01-17
NZ578411A (en) 2011-06-30
AR064921A1 (es) 2009-05-06
EP2118067B1 (en) 2013-05-08
CL2008000119A1 (es) 2008-05-16
EP2118067A1 (en) 2009-11-18
CA2675676A1 (en) 2008-07-24
JP2010515770A (ja) 2010-05-13
CN101679287B (zh) 2013-03-27
PA8766201A1 (es) 2008-11-19
CO6351782A2 (es) 2011-12-20
BRPI0806665A2 (pt) 2011-09-06
ZA200904943B (en) 2010-09-29
EA200900831A1 (ru) 2010-02-26
MX2009007615A (es) 2009-07-27
KR20090116707A (ko) 2009-11-11
UA98317C2 (ru) 2012-05-10
SV2009003334A (es) 2010-08-09
AU2008206759A1 (en) 2008-07-24
CR10930A (es) 2013-02-12

Similar Documents

Publication Publication Date Title
PA8766201A1 (es) Metodos de fabricacion y uso de compuestos y composiciones
ECSP088774A (es) Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmacéuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricación.
ECSP066391A (es) [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
PA8836101A1 (es) Inhibidores alfa7 nicotínicos del receptor de acetilcolina
CO6331340A2 (es) Pirrolo-pirimidinas y pirrolo piridinas
UY28376A1 (es) Agentes terapéuticos
ECSP088804A (es) Antagonistas de los piridil amida de los canales de calcio de tipo t
UY28752A1 (es) Agentes terapeuticos
ECSP088283A (es) Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
CR9786A (es) Compuestos de bencimidazol-tiofeno
CL2008003096A1 (es) Compuestos derivados de piperidino-dihidrotienopirimidinas; inhibidores pde4; composicion farmaceutica que los comprende; y uso en el tratamiento de trastornos o enfermedades de las vias respiratorias o gastrointestinales, como tambien enfermedades inflamatorias de las articulaciones u ojos, entre otras.
CL2009000696A1 (es) Compuestos polisustituidos derivados de 2-aril-6-fenil-imidazo[1,2-a]piridinas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento y la prevencion de enfermedades neurodegenerativas, de traumatismos cerebrales y epilepsia, enfermedades psiquiatricas, enfermedades inflamatorias, entre otras.
ECSP088366A (es) 1,2-diarilimidazoles para uso como moduladores de cb1
CR10458A (es) Compuestos de triazolopirazina utiles para el tratamiento de enfermedades degenerativas e inflamatorias
BRPI0507312A (pt) derivados de quinolina para uso como inibidores micobacterianos
SV2008003032A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
CL2008001658A1 (es) Composicion farmaceutica que comprende mesilato de imatinib amorfo y un principio de formulacion que estabiliza la forma amorfa; y su uso para tratar leucemia mieloide cronica avanzada y recientemente diagnosticada, leucemia mielomonocitica cronica, glioblastoma multiforme, entre otras.
UY31322A1 (es) Amidas heterocíclicas y sus métodos de uso-975
CL2009000281A1 (es) Compuestos derivados de 5,6-dihidro-pirrolo-[2,1-a]-isoquinolinas y pirrolo-[2,1-a]-isoquinolinas; composicion farmaceutica que comprende a dichos compuestos; y uso para el tratamaiento de trastornos de la fertilidad.
ECSP088250A (es) Derivados de pirazol como agentes terapéuticos
AR065368A1 (es) Anticuerpos para moleculas de ige
AR074379A1 (es) Inhibidor de triazolotiadiazola de la proteina quinasa c-met
AR057239A1 (es) Inmunoglobulinas
CL2008000318A1 (es) Compuestos derivados de n-(2,3,4,4a,5,6-hexahidro-1h-pirazino(1,2-a)quinolina-8-carbonil)bencenosulfonamida; procedimiento de preparacion; composicion farmaceutica que contiene a dichos compuestos; y su uso para tratar el cancer de vejiga, cerebro, m
CL2011000832A1 (es) Compuestos derivados de tieno[2,3-d]pirimidin-4-amina sustituidos, antagonista de los receptores de adenosina a2a; composicion farmaceutica; y su uso para tratar trastornos neurodegenerativos o motores, entre otras enfermedades.